Sustained Remission with No Dose Escalation after Re-induction with Certolizumab Pegol in Patients with Crohnʼs Disease Exacerbation: 1-Year Results from PRECiSE 4
Bibliographic record
Abstract
Purpose: Patients (pts) with active Crohn's disease (CD) who experienced disease exacerbation on either certolizumab pegol (CZP) or placebo maintenance therapy in PRECiSE 1 (P1)1 and PRECiSE 2 (P2)2 were re-induced with CZP in PRECiSE 4 (P4). The purpose of this analysis is to evaluate the 1-year sustainability of remission (total Harvey-Bradshaw Index [HBI] score of ≤4 points) of CZP 400 mg every-4-weeks (q4w) among these pts. Methods: In P1 (NCT00152490), pts (n=662) were randomized to either CZP 400 mg or placebo at Wk 0 and then continuous therapy with the same treatment during Wks 6-26. In P2 (NCT00152425), pts who responded to induction therapy with CZP at Wk 6 (n=428) were randomized to continuous therapy with CZP or placebo (drug interruption) during Wks 6-26. Pts who had an exacerbation of symptoms after Wk 2 for P1 and after Wk 6 for P2 could enter P4 (NCT00160706), an open-label extension study. A total of 310 pts entered P4 from P1 and P2. In P4, pts received CZP 400 mg at Wks 0, 2, and 4 (from disease exacerbation) followed by maintenance therapy with CZP 400 mg q4w. Results: A total of 108 pts were in HBI remission at Wk 8. After 1 year of CZP 400 mg q4w maintenance therapy, remission was maintained in 75% (observed case) and 45% (nonresponder imputation [NRI]) patients (Table). At the cutoff for this 1-year analysis, 68/108 (63%) pts were still on-study while 40 (37%) pts discontinued. Most adverse events (AEs) reported were of mild to moderate intensity. There were 26 serious AEs in 20 pts. There were no concerns related to laboratory tests or vital signs.Table: P4 patients in remission at wk 52, % ( n / N )Conclusion: Among P1 and P2 pts with active CD and disease exacerbation who entered P4, CZP 400 mg re-induction followed by CZP 400 mg q4w maintenance therapy successfully recaptured and maintained remission. Pts may have a durable response to a recapture approach to managing disease exacerbation rather than ongoing dose escalation. Further study of which pts will be more likely to benefit from this approach is needed.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.002 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.002 | 0.002 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.001 |
| Research integrity | 0.001 | 0.002 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".